Clinical Report: Special Series: Advances in Molecular Pathology

Overview

The Pathologist’s special series presents recent developments, expert perspectives, and stories in precision diagnostics. It also focuses on practical opportunities and challenges in bringing advanced sequencing technologies into clinical practice.

Background

Molecular pathology supports precision diagnostics by applying molecular methods to clinical testing. The collection frames molecular innovation as an evolving area and brings together perspectives from across the field. Related coverage includes a retrospective discussion with Ian Cree on developments in molecular pathology over the decade since an earlier interview. Other related material addresses genomic profiling in advanced and metastatic solid tumors and the progress and pitfalls of molecular diagnostic assays and tissue selection.

Data Highlights

The supplied article context contains no numerical study results or trial data.

Key Findings

• The special collection covers breakthroughs, expert perspectives, and stories from across precision diagnostics.
• It includes practical insights into opportunities and challenges associated with implementing advanced sequencing technologies in clinical settings.
• A related interview revisits molecular pathology developments with Ian Cree, who was previously Head of the WHO Classification of Tumors Group at IARC and is now Director at CanTech Limited.
• A 2024 ASCO Annual Meeting abstract addresses multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors.
• A 2003 Journal of Clinical Oncology editorial addresses molecular diagnostic assays, tissues, progress, and pitfalls.

Clinical Implications

The collection identifies implementation of advanced sequencing technologies as a practical clinical consideration, while the supplied context does not specify particular testing protocols or recommendations. Related sources address genomic profiling and assay and tissue considerations, but the provided material does not report their detailed findings.

Conclusion

The series offers a broad overview of molecular innovation in precision diagnostics and highlights implementation as an important topic. The supplied material provides context and related references but no quantitative outcomes or specific clinical recommendations.

Related Resources & Content

1. The Pathologist, Molecular Evolution, 2024 -- Molecular Evolution
2. ASCO Publications, 2024 -- Multi-specimen comprehensive genomic profiling for diagnostic disambiguation in advanced and metastatic solid tumors
3. Allegra C, Sargent D, Journal of Clinical Oncology, 2003 -- Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls
4. the pathologist — What’s New in Molecular Pathology?
5. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice
6. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3 | Journal of Clinical Oncology
7. CAP Puts Patient Safety and Regulatory Clarity at the Forefront with New Laboratory Checklist
8. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial | Nature Medicine
9. 553P Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY - Annals of Oncology
10. Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)—an AIO/ABCSG trial - Annals of Oncology
11. Colon cancer: ctDNA-guided adj chemo not ready for prime time? | ESMO
12. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3
13. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice